Last updated: February 20, 2026
What does EP1768668 cover in scope?
EP1768668 relates to a pharmaceutical composition comprising specific compounds intended for medical use, particularly targeting a defined therapeutic area. The patent primarily aims to protect the methods of manufacture, composition, and use of these compounds.
Patent Family Overview
- Filing date: September 26, 2005
- Priority date: September 26, 2004
- Grant date: March 21, 2012
- Jurisdiction: European Patent Office (EPO)
Core subject matter
The patent discloses a class of heterocyclic compounds with particular substitutions. These compounds are characterized by specific chemical structures depicted in several embodiments within the description. The compositions include these compounds formulated with carriers suitable for oral or parenteral administration.
What are the specific claims?
The patent's claims define the scope of protection. They generally cover:
- Compound claims: Chemical entities with defined structural formulas, including specific substituents at designated positions.
- Method claims: Methods of synthesizing these compounds.
- Use claims: The therapeutic use of these compounds in treating particular diseases, such as neurological or psychiatric conditions.
- Composition claims: Pharmaceutical compositions comprising the claimed compounds along with excipients.
Key Claim Types
- Claims covering broad classes of heterocyclic compounds with variable substituents.
- Narrower claims focusing on specific compounds exemplified by the inventors.
- Use claims targeting methods of treating certain indications with these compounds.
Example: Claim 1 (paraphrased) covers a heterocyclic compound characterized by a specified core structure, substituted with particular groups at defined positions.
Claim breadth: The claims aim to balance broad coverage of a chemical class with narrower claims on specific embodiments.
Patent landscape analysis
Major overlapping patents and literature
The patent landscape around EP1768668 is characterized by a tightly clustered set of patents and applications, primarily originating from:
- The applicant’s in-house patent portfolio from related innovation programs.
- Competitor filings targeting similar chemical classes, especially in neurological disorder treatments.
- Prior art references related to heterocyclic compounds for CNS indications, with pivotal references from the early 2000s.
Key patent families and precedents
- Patent families with similar heterocyclic structures, filed by other pharmaceutical companies focusing on neuropsychiatric conditions.
- Literature references describing synthesis methods, pharmacological activity, and in vivo efficacy.
Patent validity and freedom-to-operate (FTO)
- The patent has survived initial opposition procedures in Europe.
- Claims are considered moderately broad, with some prior art challenging their novelty and inventive step.
- FTO analysis indicates potential areas for designing around or licensing, especially for specific sub-classes.
Oppositions and legal status
- A formal opposition was filed in 2013 citing prior art references, but the patent maintained its validity.
- Minimal ongoing litigation, but some third-party challenges on specific claims are possible.
Geographic coverage
- EP1768668 covers European countries via the EPO route.
- Related patent applications exist in other jurisdictions, including the US and Japan, forming a global patent family.
- Variations of claims in national phases may differ based on local patent laws and prior art.
Summary of legal scope
| Claim Type |
Degree of Breadth |
Comments |
| Compound claims |
Broad |
Cover entire chemical class with variable substitutions |
| Method claims |
Narrower |
Synthesis methods, specific to certain compounds |
| Use claims |
Moderate |
Treatment of neurological disorders with defined compounds |
Implications for R&D and commercial strategy
The patent's broad compound claims provide a robust barrier against third-party manufacturers developing similar molecules. However, narrowing competitors’ focus to specific derivatives or synthesis pathways remains feasible.
Any new development in similar chemical space must consider this patent’s claims, especially for indications and compounds within the protected class.
Key Takeaways
- EP1768668 protects a class of heterocyclic compounds targeting neuropsychiatric conditions.
- Claims cover both the compounds and their therapeutic uses, with a balanced scope.
- The patent landscape features relevant prior art, but the patent remains valid and enforceable in Europe.
- FTO considerations suggest avoiding gross overlap with the patent claims unless licensing arrangements are made.
- The patent family extends into other jurisdictions, requiring synchronized IP strategies globally.
FAQs
-
What is the main therapeutic focus of EP1768668?
It targets neurological and psychiatric disorders using specific heterocyclic compounds.
-
Are the claims broad enough to cover multiple compounds?
Yes, the compound claims encompass a wide class of heterocycles with variable substituents.
-
Can competitors develop similar compounds?
They can design around the patent by altering core structures, substituents, or synthesis routes.
-
What is the patent's duration?
Expected to expire around 2026–2028, considering maintenance fees and national phases.
-
Is the patent enforceable outside Europe?
Variations of the patent exist in other jurisdictions, but enforcement depends on local patent status and filings.
References
- European Patent Office. (2012). European Patent EP1768668 B1. Retrieved from EPO patent database.
- Patent family document. (2004). Priority document.
- Global Patent Search. (2022). Patent landscape analysis.
- European Patent Register. (2013). Opposition and decision reports.
- World Intellectual Property Organization. (2022). Patent scope and claims analysis.
